CRISPR Therapeutics AG
NASDAQ:CRSP
51.88 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||
| Net Income
| -153.61 | -650.175 | 377.661 | -348.865 | 66.858 | -164.981 | -68.357 | -23.202 | -25.828 | -6.8 |
| Depreciation & Amortization
| 19.837 | 24.172 | 17.953 | 9.184 | 4.725 | 3.519 | 3.024 | 0.925 | 0.127 | 0.038 |
| Deferred Income Tax
| 0 | 0 | 0 | 0 | 0 | 4.275 | 0 | -53.708 | -0.02 | 0 |
| Stock Based Compensation
| 81.028 | 97.947 | 102.39 | 66.018 | 44.057 | 34.985 | 18.873 | 10.844 | 3.684 | 0.695 |
| Change In Working Capital
| -193.585 | 19.845 | 26.859 | 33.44 | -48.43 | 10.55 | -25.391 | 1.781 | 81.368 | 1.534 |
| Accounts Receivables
| -200 | 0.305 | -0.161 | -0.045 | -0.011 | 2.538 | 0.531 | -2.818 | -0.339 | 0 |
| Inventory
| 23.329 | 0 | -37.514 | -25.747 | -5.025 | 332.299 | -551.298 | -1.088 | 0 | 0 |
| Accounts Payables
| -20.247 | 5.164 | 37.514 | 25.747 | 5.025 | -323.282 | 546.62 | 3.86 | 0 | 0 |
| Other Working Capital
| 3.333 | 14.376 | 27.02 | 33.485 | -48.419 | -1.005 | -21.244 | 1.827 | 81.707 | 1.534 |
| Other Non Cash Items
| -14.045 | 12.47 | 14.109 | 1.857 | -10.533 | 15.413 | 1.754 | 8.05 | 0.097 | -0.26 |
| Operating Cash Flow
| -260.375 | -495.741 | 538.972 | -238.366 | 56.677 | -96.239 | -70.097 | -55.31 | 59.428 | -4.793 |
| Investing Activities: | ||||||||||
| Investments In Property Plant And Equipment
| -11.97 | -37.188 | -81.705 | -18.358 | -6.684 | -2.773 | -7.814 | -3.016 | -1.154 | 0 |
| Acquisitions Net
| 2.5 | 221.467 | 953.725 | 522.812 | 8.009 | 0 | 0 | -0.1 | 0 | 0 |
| Purchases Of Investments
| -1,065.911 | -1,417.8 | -1,509.327 | -593.998 | 0 | 0 | -0.5 | -0.1 | 0 | 0 |
| Sales Maturities Of Investments
| 1,452.528 | 1,196.333 | 555.602 | 71.186 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| -2.5 | -221.467 | -953.725 | -522.812 | 8.009 | 0 | -0.5 | 35 | 0 | 0 |
| Investing Cash Flow
| 374.647 | -258.655 | -1,035.43 | -541.17 | 1.325 | -2.773 | -8.314 | 31.884 | -1.154 | 0 |
| Financing Activities: | ||||||||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -35.01 | -38.239 | 0 |
| Common Stock Issued
| 32.721 | 38.592 | 250.945 | 982.289 | 415.019 | 307.053 | 2.608 | 89.061 | 58.494 | 0.022 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | -0.057 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 29.943 | 38.592 | 250.945 | 33.863 | 15.964 | 8.938 | 2.608 | 94.159 | 96.733 | 5.101 |
| Financing Cash Flow
| 62.664 | 38.592 | 250.945 | 1,016.152 | 430.983 | 315.934 | 2.608 | 183.22 | 96.733 | 5.123 |
| Other Information: | ||||||||||
| Effect Of Forex Changes On Cash
| 0.073 | -0.08 | -0.011 | 0.04 | 0.015 | -0.022 | 0.041 | -0.235 | 0.009 | 0.254 |
| Net Change In Cash
| 177.008 | -715.884 | -245.524 | 236.656 | 489 | 216.9 | -75.762 | 159.559 | 155.016 | 0.584 |
| Cash At End Of Period
| 401.068 | 224.06 | 939.944 | 1,185.468 | 948.812 | 459.812 | 239.758 | 315.52 | 155.961 | 0.945 |